Ajit S. Gill (BT/EE/1969)
has set up the Joy Gill chair in honour of his parents. This chair
is for a young faculty member in the department of Biological Science
and Bioengineering. Mr. Gill joined USVP as an Entrepreneur-in-Residence
in December 2006 after 14 years at Nektar Therapeutics (previously
Inhale Therapeutic Systems) where he was the CEO for the last 8 years.
He joined the company as CFO, soon after it received its Series-A
financing in 1992, and also served as head of R&D and operations
for several years. He led the development of Nektar's inhaled insulin
product, Exubera, in partnership with Pfizer and Mr. Gill retired
from Nektar when Exubera received regulatory approval from the FDA
(US) and the EMEA (EU). During his time at Inhale/Nektar, Mr. Gill
managed the transformation of the business model from a pulmonary
delivery company, focussed on protein and peptide delivery, to a proprietary
products company with several blockbuster products on the market incorporating
its drug delivery technologies and a market cap of over $2 billion
(fully diluted) when he stepped down as CEO. Prior to joining Inhale,
Mr. Gill worked for many years in the computer business in a variety
of roles in general management, finance, business development and
operations. Immediately before joining Inhale, he was General Manager
of Interactive Systems Products Business, a subsidiary of Eastman
Kodak. Mr. Gill obtained his M.S. in electrical engineering from the
University of Nebraska and his MBA from the University of Western
Occupant (Prof. S. Ganesh)
Professor S. Ganesh, Department of Biological Sciences and Bioengineering
is Joy Gill Chair Professor from November 2010 to November 2013. Prof.
Ganesh was born on 23rd May, 1968 in Chittoor (AP). He did his PhD from
Banaras Hindu University (BHU) in Varanasi. Prof. Ganesh joined the Department
of Biological Sciences and Bioengineering (BSBE) at IIT-Kanpur in April
2002. Prof. Ganesh’s research interests are in the areas of molecular
genetics of human disorders. His group works on the neurodegenerative
disorders, a group of central nervous system dysfunctions characterised
by the progressive loss of neural tissues, movement abnormalities, progressive
decline in intellectual and cognitive functions, and in certain cases
early death. A major research focus of Prof. Ganesh's group therefore
is to identify and characterize molecular players in neurodegenerative
pathways and to identify therapeutic targets. For this, he conducts genetic
screens in affected families and utilize cellular/animal models for testing
and validating the hypothesis. Discovery of critical players in neurodegeneration
is undoubtedly the first step towards developing effective therapeutics.
Prof. Ganesh is a recipient of several awards including the Rajib Goyal
Prize in Life Sciences (Goyal Foundation, Kurukshetra University), DAE-SRC
Outstanding Research Investigator Award (Dept. of Atomic Energy, Govt.
of India), B.M. Birla Science Prize in Biology (BM. Birla Science Centre,
Hyderabad), National Bioscience Award for Career Development (Dept. of
Biotechnology, Govt. of India) and the Scopus Young Scientist Award in
Biological Sciences (Elsevier India).
Sankararamakrishnan (BSBE), June 2007 to June 2010.